Development, disease and degeneration in schizophrenia: a unitary pathophysiological model

被引:160
作者
Keshavan, MS [1 ]
机构
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA
关键词
schizophrenia; glutamate; premorbid deficits; onset; degeneration; dopamine;
D O I
10.1016/S0022-3956(99)00033-3
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
In recent years, several pathophysiological models of schizophrenia, i.e. the early and late brain neurodevelopmental and post-illness onset neurodegenerative models, have been proposed and theorists have often argued as if these explanations are mutually exclusive. We propose that all these mechanisms may interact cumulatively during successive critical 'windows of vulnerability' during brain development and during the early course of the illness to lead to the clinical manifestations of the illness. Early brain insults may lead to dysplasia of selective neural networks that account for the premorbid cognitive and psychosocial dysfunction seen in many;patients. The onset of psychosis in adolescence may be related to an excessive elimination of synapses and secondarily, phasic dopaminergic overactivity. Following illness onset, these neurochemical alterations in relation to continuing untreated psychosis may lead to further neurodegenerative processes. A reduction in tonic glutamatergic neurotransmission and a phasic glutamatergic excess can potentially predispose to these processes and may have considerable explanatory power. This hypothesis is consistent with central characteristics of schizophrenia such as premorbid manifestations, adolescent onset, functional decline early in this illness, cognitive impairments, the role of dopamine and the role of genes and environment in pathophysiology. This 'three hit' model extends similar integrative conceptualization by other investigators and generates testable predictions of relevance to future pathophysiology and treatment research in schizophrenia. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:513 / 521
页数:9
相关论文
共 87 条
[1]  
Akbarian S, 1996, J NEUROSCI, V16, P19
[2]  
AKBARIAN S, 1993, ARCH GEN PSYCHIAT, V50, P169
[3]  
ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P943
[4]  
[Anonymous], NEURODEVELOPMENT ADU
[5]   Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence [J].
Arnt, J ;
Skarsfeldt, T .
NEUROPSYCHOPHARMACOLOGY, 1998, 18 (02) :63-101
[6]   OXIDATIVE STRESS-INDUCED BY GLUTAMATE RECEPTOR AGONISTS [J].
BONDY, SC ;
LEE, DK .
BRAIN RESEARCH, 1993, 610 (02) :229-233
[7]   STRUCTURAL BRAIN ABNORMALITIES AS INDICATORS OF VULNERABILITY TO SCHIZOPHRENIA [J].
CANNON, TD ;
MARCO, E .
SCHIZOPHRENIA BULLETIN, 1994, 20 (01) :89-102
[8]  
CARTER CS, IN PRESS ADV PSYCHIA
[9]  
Cheramy A, 1990, J Neural Transm Suppl, V29, P183
[10]   POSITRON EMISSION TOMOGRAPHY STUDY OF HUMAN-BRAIN FUNCTIONAL-DEVELOPMENT [J].
CHUGANI, HT ;
PHELPS, ME ;
MAZZIOTTA, JC .
ANNALS OF NEUROLOGY, 1987, 22 (04) :487-497